Jiangsu Hengrui, a 55-year-old drugmaker that has become one of China’s leading forces in biotech, expects net proceeds of about 9.4 billion Hong Kong dollars …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Visited 1 times, 1 visit(s) today
